An investigational in vivo base editing medicine targeting ANGPTL3, VERVE-201, achieves potent and LDLR-independent liver editing in mouse models

25 August 2023 (07:30 - 18:30)

Organised by:

Sign in for access options

Sign in to view the resources

Sign in for access options

About the speaker

Doctor Amit Khera

Verve Therapeutics, Boston (United States of America)

5 More presentations in this session

Presentation thumbnail

Course of the effects of LDL-cholesterol reduction on cardiovascular risk over time: a meta-analysis of 59 trials

Doctor P. Burger (Utrecht, NL)

Abstract Slides Video

Presentation thumbnail

Attainment of LDL-cholesterol goals in patients with previous myocardial infarction: a real-world cross-sectional analysis

Mr D. Gomes (Lisbon, PT)

Abstract Slides Video

Presentation thumbnail

Lipoprotein(a) is not a causal factor for the development of diabetes - a two-sample Mendelian randomization study.

Associate Professor T. Osadnik (Zabrze, PL)

Abstract Slides Video

Presentation thumbnail

Cardiovascular outcomes in patients with coronary artery disease and elevated lipoprotein(a): Implications for the OCEAN(a)-Outcomes trial population

Doctor B. Weber (Dallas, US)

Abstract Slides Video

Presentation thumbnail

Effects of icosapent ethyl on residual cardiovascular risk according to predicted baseline risk: results from REDUCE-IT

Doctor P. Burger (Utrecht, NL)

Abstract Slides Video

Access the full session

Session thumbnail

What's new in lipid lowering?

The Event

Event poster

ESC Congress 2023

25 August - 28 August 2023

You may be interested in

Congress Presentation

Lipid control in cardiovascular patients

Congress Presentation

Fix the plaque, fight the lipids: why low-density lipoproteins still matter after percutaneous coronary intervention

Congress Presentation

What’s new in LDL lowering?

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources